【摘要】 目的　比较曲美布汀与莫沙必利、多潘立酮治疗功能性消化不良的疗效及安全性。方法　将 2 0 0例功能性消化不良病人随机分为 3组 ,曲美布汀组 80例 ,予曲美布汀 10 0mg ,3次 d ;莫沙必利组 6 0例 ,予莫沙必利 5mg,3次 d ;多潘立酮组 6 0例 ,予多潘立酮 10mg ,3次 d。疗程均为 4周 ,观察症状变化情况并做对比分析。结果　总有效率曲美布汀组 87.5 % ,莫沙必利组为 90 .0 % ,多潘立酮组为 6 1.7%。曲美布汀、莫沙必利 2组疗效差异无显著意义(P >0 .0 5 ) ,曲美布汀组疗效优于多潘立酮组 (P <0 .0 1)。不良反应 :曲美布汀、莫沙必利、多潘立酮组分别为5 .0 %、8.0 %、6 .7% (P >0 .0 5 )。结论　曲美布汀治疗功能性消化不良近期疗效显著、安全性好。更多还原

【Abstract】 Objective To compare the effect and safety of trimebutine,mosapride and domperidone in the treatment of functional dyspepsia (FD). Methods Two hundred patients with functional dyspepsia were randomly divided into three groups.The patients of trimebutine group were treated with trimebutine,100 mg,three times a day.Mosapride was given 5 mg,three times a day in contrast. The patients of another control group were given each 10 mg domperidone in same way. The course of treatment lasted 4 weeks. Results The total effect rate of treatment group was 87.5%.It was significantly higher than that of domperidone group(61.7%),P <0.01.But there was not differences between trimebutine group and mosapride group(87.5% vs 90.0%),P > 0.05 . Adverseactions of trimebutine group were similar to those of mosapride group and domperidone group (P >0.05). Conclusions Trimebutine is shown to be a safe medicine,and it is effective in treatment of FD and similar to mosapride,superior to domperidone.更多还原